S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Strongbridge Biopharma Stock Forecast, Price & News

+0.01 (+0.36 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $2.78
50-Day Range
MA: $3.10
52-Week Range
Now: $2.78
Volume1.22 million shs
Average Volume881,249 shs
Market Capitalization$186.94 million
P/E RatioN/A
Dividend YieldN/A
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.
Strongbridge Biopharma logo


Recap: Strongbridge Biopharma Q4 Earnings
March 3, 2021 |  benzinga.com
Strongbridge Biopharma: Q4 Earnings Snapshot
March 3, 2021 |  finance.yahoo.com
Preview: Strongbridge Biopharma's Earnings
March 2, 2021 |  benzinga.com
Is SBBP A Good Stock To Buy Now?
December 14, 2020 |  finance.yahoo.com
Strongbridge Biopharma Plcto Host Earnings Call
October 29, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SBBP
Year FoundedN/A



Sales & Book Value

Annual Sales$21.71 million
Book Value$1.33 per share


Net Income$-49,450,000.00
Net Margins-149.79%


Market Cap$186.94 million
Next Earnings Date5/5/2021 (Estimated)


Overall MarketRank

1.45 out of 5 stars

Medical Sector

560th out of 1,972 stocks

Pharmaceutical Preparations Industry

261st out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
+0.01 (+0.36 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SBBP News and Ratings via Email

Sign-up to receive the latest news and ratings for SBBP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions

Is Strongbridge Biopharma a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Strongbridge Biopharma stock.
View analyst ratings for Strongbridge Biopharma
or view top-rated stocks.

What stocks does MarketBeat like better than Strongbridge Biopharma?

Wall Street analysts have given Strongbridge Biopharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Strongbridge Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Strongbridge Biopharma's next earnings date?

Strongbridge Biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Strongbridge Biopharma

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) posted its quarterly earnings data on Tuesday, March, 2nd. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. Strongbridge Biopharma had a negative trailing twelve-month return on equity of 65.85% and a negative net margin of 149.79%.
View Strongbridge Biopharma's earnings history

How has Strongbridge Biopharma's stock been impacted by Coronavirus (COVID-19)?

Strongbridge Biopharma's stock was trading at $2.32 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SBBP shares have increased by 19.8% and is now trading at $2.78.
View which stocks have been most impacted by COVID-19

What guidance has Strongbridge Biopharma issued on next quarter's earnings?

Strongbridge Biopharma updated its FY 2021 Pre-Market earnings guidance on Wednesday, March, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $34-36 million, compared to the consensus revenue estimate of $35.81 million.

What price target have analysts set for SBBP?

3 brokerages have issued 12-month price targets for Strongbridge Biopharma's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Strongbridge Biopharma's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 151.8% from the stock's current price.
View analysts' price targets for Strongbridge Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Strongbridge Biopharma's key executives?

Strongbridge Biopharma's management team includes the following people:
  • Mr. John H. Johnson, Chief Exec. Officer (Age 63, Pay $765.19k)
  • Mr. Robert Matthew Lutz, Chief Financial Officer (Age 52, Pay $543.13k)
  • Mr. Richard S. Kollender CPA, M.B.A., CPA, Chief Operating Officer (Age 52, Pay $50.04k)
  • Dr. Fredric Cohen, Chief Medical Officer (Age 56, Pay $593.89k)
  • Dr. Per Marin M.D., Ph.D., Founder and Sr. Clinical Advisor
  • Mr. Peter J. Valentinsson, Sr. VP of Global Technical Operations
  • Mr. Stephen J. Long, Chief Legal Officer & Company Sec. (Age 55)
  • Mr. Brian Conner, Chief Compliance Officer
  • Mr. Dave Bonnell, Sr. VP of Sales & Marketing
  • Ms. Emily Doyle, Chief HR Officer

Who are some of Strongbridge Biopharma's key competitors?

What other stocks do shareholders of Strongbridge Biopharma own?

What is Strongbridge Biopharma's stock symbol?

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

Who are Strongbridge Biopharma's major shareholders?

Strongbridge Biopharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Ikarian Capital LLC (3.63%), Renaissance Technologies LLC (3.26%), BlackRock Inc. (3.14%), Morgan Stanley (2.90%), Stonepine Capital Management LLC (2.01%) and Hudson Bay Capital Management LP (1.90%). Company insiders that own Strongbridge Biopharma stock include Associates LLC Cdk and David N Gill.
View institutional ownership trends for Strongbridge Biopharma

Which institutional investors are selling Strongbridge Biopharma stock?

SBBP stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, and Stonepine Capital Management LLC.
View insider buying and selling activity for Strongbridge Biopharma
or view top insider-selling stocks.

Which institutional investors are buying Strongbridge Biopharma stock?

SBBP stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Worth Venture Partners LLC, BlackRock Inc., JPMorgan Chase & Co., Bank of New York Mellon Corp, Northern Trust Corp, Principal Financial Group Inc., and Morgan Stanley. Company insiders that have bought Strongbridge Biopharma stock in the last two years include Associates LLC Cdk, and David N Gill.
View insider buying and selling activity for Strongbridge Biopharma
or or view top insider-buying stocks.

How do I buy shares of Strongbridge Biopharma?

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Strongbridge Biopharma's stock price today?

One share of SBBP stock can currently be purchased for approximately $2.78.

How much money does Strongbridge Biopharma make?

Strongbridge Biopharma has a market capitalization of $186.94 million and generates $21.71 million in revenue each year. The biotechnology company earns $-49,450,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis.

How many employees does Strongbridge Biopharma have?

Strongbridge Biopharma employs 71 workers across the globe.

What is Strongbridge Biopharma's official website?

The official website for Strongbridge Biopharma is www.strongbridgebio.com.

Where are Strongbridge Biopharma's headquarters?

Strongbridge Biopharma is headquartered at 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053.

How can I contact Strongbridge Biopharma?

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]

This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.